Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Critical Gaps and Controversies in the Laser Treatment of Port Wine Birthmarks and Other Vascular Anomalies
Description
The forum discussed critical gaps and controversies in the laser treatment of port wine birthmarks and vascular anomalies, led by experts from various institutions. The presentations covered the genetic underpinnings of these conditions, emphasizing the role of genes such as GNAQ, GNA11, and others in causing these birthmarks, with a significant percentage attributed to genetic variations linked to vascular anomalies. The speakers explored treatment options and timing, emphasizing the importance of understanding patient responses to laser treatments, which can vary despite similar genotypes. Discussions highlighted the need for further research into the genetics and pathways of these anomalies to improve treatment outcomes. Innovative therapies, including targeted gene therapy and investigational drugs, were suggested as potential future directions. The discussion also acknowledged the challenges faced when managing these conditions in developing regions. Overall, the emphasis was on advancing understanding, improving patient outcomes through tailored therapies, and quantifying treatment responses effectively.
View moreConclusions
- Mosaic variants in genes that regulate cell growth and proliferation are the primary cause of port wine birthmarks.
- About 90-95% of port wine birthmarks are attributed to variants in GNAQ and GNA11 genes.
- The clinical progression of vascular anomalies remains poorly understood, with ongoing debates about whether it is due to genetic pathway activation or physiological issues.
- Responses to treatments vary significantly among patients with the same genotype, suggesting a need for personalized medicine approaches.
- There is potential for targeted therapies that inhibit specific molecular pathways involved in vascular anomalies, particularly targeting the MAPK and PI3K pathways.
- Interventions with drugs like trametinib may reduce vascular density and improve outcomes in patients with vascular anomalies.
- Current treatment strategies should include comprehensive genetic testing to guide therapy, particularly in symptomatic and refractory cases.
- There is a critical need for more robust quantitative outcome measures to assess treatment efficacy in clinical trials.
- Future research should focus on understanding the detailed downstream signaling pathways activated by these genetic variants to improve therapeutic strategies.
- Trigt W et al, Front Hum Neurosci. 03 Nov 2022; 16:2006027.
- Galligan ER, et al. J Am Acad Dermatol. 2021 Mar;84: 654-660.
- Adapted from Greene AK, Goss JA. Plast Reconstr Surg. 2018 May;141(5):709e-717e.
- Lekwuttikarn R et al, JAMA Dermatol. 2019 Feb 1;155(2):256-257.
- Venot Q et al, Nature. 2018 Jun;558(7711):540-546.
- Davies OMT, et al. Pediatr Dermatol. 2022;39:914-919; Shirley MD, et al. N Engl J Med. 2013;368:1971-1979; Huang L, et al. Arterioscler Thromb Vasc Biol. 2022;42:e27-43.
- Yin et al, Am J Dermatopathol. 2017 Oct;39(10): 747-752.
- Chen X et al, Oncogene. 2014 Sep 25; 33(39): 4724-4734.
- Schrenk et al, Nat Commun. 2023 Apr 6;14(1):1929.
- Wisinski et al, JCO Precis Oncol. 2023;7.
- Carvajal et al, J Clin Oncol 2018 Apr 20;36(12).